Cumberland Pharmaceuticals Inc.CPIXNASDAQ
Loading

Latest News

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
prnewswire.com

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Cumberland to highlight 2025 financial, international, portfolio and clinical progress NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period.

Joint U.S. Commercialization of RedHill's Talicia® Commences
prnewswire.com

Joint U.S. Commercialization of RedHill's Talicia® Commences

The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reach Focused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy 1 , THI and Cumberland will manage the launch and ongoing joint commercialization activities H.

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
prnewswire.com

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients.

Critical Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Xenetic Biosciences (NASDAQ:XBIO)
defenseworld.net

Critical Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Xenetic Biosciences (NASDAQ:XBIO)

Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Valuation and Earnings This table compares Cumberland

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript
seekingalpha.com

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript

Cumberland Pharmaceuticals Inc. ( CPIX ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Emily Kent A. Kazimi - Founder, Chairman, President & CEO Todd Anthony - Vice President of Organizational Development John Hamm - VP & CFO Presentation Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Third Quarter 2025 Financial Report and Company Update.

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
prnewswire.com

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn. , Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd.

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
prnewswire.com

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is: The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy 1  Listed first-line H.

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
prnewswire.com

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn. , Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group purchasing agreement with Premier, Inc. Effective October 1, 2025 the product addition allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Vibativ® in both the 12-vial carton and the newly introduced 4-vial Starter Pak.